ヘリコバクター・ピロリに対する新しい抗生物質候補
Shanzhi Wang1, Scott A Cameron1, Keith Clinch2
1Department of Biochemistry, Albert Einstein College of Medicine , New York, New York, 10461, United States.
Journal of the American Chemical Society
|October 24, 2015
まとめ
ヘリコバクター・パイロリ (H. pylori) を標的とする新薬候補は,強力な抑制と細胞浸透を示しています. これらの新しい化合物は H. pylori に対して有効であり,既存の抗生物質の有望な代替品です.
科学分野:
- 微生物学
- 薬物の発見
- 生物化学
背景:
- ヘリコバクター・パイロリ (H. pylori) 感染症は,世界人口の50%以上に影響を与え,胃潰瘍を引き起こし,胃がんのリスクを増やす.
- H. pylori の抗生物質耐性は 独特の細菌経路を標的とした新しい治療戦略を必要とします.
- H. pyloriは5'-メチルチオアデノシン/S-アデノシルホモシステイン核酸化酵素 (MTAN) を含む異常なメナキノン生物合成経路を使用する.
研究 の 目的:
- 新しい抗生物質として可能性のあるH. pylori MTANの新しい阻害剤を特定し,検証する.
- MTAN阻害とH. pylori成長阻害のための構造的支架を探求する.
- MTAN阻害剤がグラム陰性H. pylori細胞膜に浸透する能力を評価する.
主な方法:
- H. pylori MTANの16の移行状態アナログ阻害剤の合成と特徴づけ
- MTANへの阻害剤結合親和度 (解離定数) の決定
- H. pyloriの成長抑制 (IC90値) と細胞浸透の評価
- MTAN活性部位内の阻害剤結合モードを明らかにするためのX線結晶学.
主要な成果:
- 16のMTAN阻害剤は50 pM以下の解離定数を示し,緊密な結合を示した.
- これらの阻害剤のうち10は,IC90値が0. 01μg/ ml未満で,H. pyloriの増殖を効果的に阻害した.
- 阻害剤は強力な活性と細胞浸透性を示し,一般的なH. pylori抗生物質を16〜2000倍上回った.
結論:
- MTANはH. pyloriに対する有効な標的薬である.
- MTANの新型トランジション状態アナログ阻害剤は,新しいH. pylori抗生物質として有意な可能性を示しています.
- これらの化合物は,その効能と耐性メカニズムを克服する能力により,現在の治療法に有望な代替手段を提供します.
さらに関連する動画
関連する概念動画
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.2K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.2K
Peptic Ulcer Disease IV: Management
646
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
646
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
1.3K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.3K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
787
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
787
Peptic Ulcer
30
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
30


